Last reviewed · How we verify
Immunotherapy monotherapy
Immune checkpoint inhibitor
Immune checkpoint inhibitor Used for Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | Immunotherapy monotherapy |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This class of drugs works by blocking the interaction between PD-1 and PD-L1, allowing the immune system to attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer
- Melanoma
Common side effects
- Pneumonitis
- Colitis
- Hypophysitis
- Arthralgia
- Fatigue
Key clinical trials
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment (PHASE1)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (PHASE1)
- Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (PHASE2)
- Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma (PHASE1, PHASE2)
- Fiber-Boost Randomized Controlled Trial (NA)
- Study of CHS-114 in Participants With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |